Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Roquefort Investments PLC ( (GB:ROQ) ) has shared an update.
Roquefort Therapeutics PLC announced that its Executive Chairman, Stephen West, has purchased 2,400,000 ordinary shares of the company at an average price of 1.50 pence per share, totaling £36,000. This acquisition increases Mr. West’s total holdings to 9,110,853 shares, representing 5.79% of the company’s issued capital. This move is significant as it demonstrates confidence in the company’s strategic direction and potential for growth in the competitive biotech industry.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, focused on developing first-in-class medicines in the high-value and high-growth immunology and oncology markets. The company has a portfolio of five novel patent-protected pre-clinical anti-cancer and immunology assets.
Average Trading Volume: 1,052,327
Technical Sentiment Signal: Sell
Current Market Cap: £2.05M
For an in-depth examination of ROQ stock, go to TipRanks’ Overview page.